Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 18/06/2024 BST 5-day change 1st Jan Change
306 USD +0.89% Intraday chart for Amgen Inc. +1.76% +6.24%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto DJ
Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer MT
Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto CI
Sector Update: Health Care Stocks Softer Friday Afternoon MT
RBC Raises Price Target on Amgen to $332 From $328, Maintains Outperform Rating MT
RBC Raises Price Target on Amgen to $332 From $328, Maintains Outperform Rating MT
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6% MT
Transcript : Amgen Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
AbbVie's tight grip on Humira market raises concerns about biosimilars RE
Transcript : Amgen Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:00 AM
Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints MT
Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD DJ
Amgen's drug meets main goal in late-stage study for rare disease RE
Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd) CI
Amgen Inc. Appoints Dr. Mary E. Klotman as Director CI
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval DJ
Weight-loss drug forecasts jump to $150 billion as supply grows RE
Sandoz: Marketing authorization for Wyost and Jubbonti in the EU CF
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test MT
Transcript : Amgen Inc. - Special Call
HSBC Adjusts Price Target on Amgen to $356 From $322 MT
Amgen and AstraZeneca's Lung Disease Drug Study Reports Mixed Results MT
Amgen Announces the Results of the Phase 2a COURSE Trial Evaluating Tezspire® (Tezepelumab-Ekko) in People with Moderate to Very Severe Chronic Obstructive Pulmonary Disease CI
US FDA approves Amgen drug for small cell lung cancer RE
Chart Amgen Inc.
More charts
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
306 USD
Average target price
316.4 USD
Spread / Average Target
+3.42%
Consensus
  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. News Amgen Inc.
  5. Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW